A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis

Clinical trial NCT02583594 · COMPLETED

Trial details

NCT number: NCT02583594
Sponsor: Genzyme, a Sanofi Company
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Progressive Multiple Sclerosis

Start date: 2015-12-06
Primary completion: 2016-03-01
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.